Taking people in United StatesPhase 4
Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
Key facts
- Who runs it
- Children's Mercy Hospital Kansas City
- Where
- Kansas City, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 40 people, planned
- Started
- 31 Jul 2025
- Expected to end
- 31 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Micronized progesterone 200 MG
- Micronized Progesterone 100 MG
- Record updated
- 25 August 2026
Who can take part
- Age
- 12 years to 20 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency
- Prescribed adult dosing* of transdermal or oral estradiol for estrogen replacement therapy; *Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg/day of transdermal estradiol, or (i.e. 50-200μg/day of transdermal estradiol or 2-4mg/day oral estradiol)
- Have achieved menarche
Who cannot take part
- Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place
- Having received depot medroxyprogesterone within one year prior to study recruitment
- Disclosure of sexual activity and desire for contraception
- Non-English or non-Spanish speaking
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 20 years old?
Where in United States
- Children's Mercy HospitalKansas City, United StatesContact: Allie RanalloTaking people
About the trial
What the trial wants to find out
This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).
The 2 groups in the trial
- Sequential progesterone supplementationExisting treatment, for comparison
Oral micronized progesterone 200mg for the first 12 days of a 30 to 31-day cycle.
Treatment: Micronized progesterone 200 MG
- Continuous progesterone supplementation:Existing treatment, for comparison
Oral micronized progesterone 100mg daily taken throughout the 30 to 31-day cycle.
Treatment: Micronized Progesterone 100 MG
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome: A Non-randomized Prospective Trial (The BOOST Study)
- Fit questions
- Built from NCT06834594, who can take part
- Record updated
- 25 August 2026